Change Country
Welcome to LuxembourgWelcome
Please read the important information below before continuing to our website

The Lyxor ETFs on this website may be restricted for certain individuals or in certain countries pursuant to the national regulations applicable to those individuals or countries. It is therefore your responsibility to ensure that you are authorised to invest in the Lyxor ETFs on this website. 


If you are an investor in the United Kingdom, please go to  

If you are an investor in the Netherlands, please go to  

If you are an investor in Italy, please go to  

If you are an investor in Spain, please go to  

If you are an investor in Austria, please go to  

If you are an investor in Germany, please go to   

If you are an investor in Singapore, please go to  

If you are an investor in Switzerland, please go to  

If you are an investor in Belgium, please go to  

If you are an investor in Poland, please go to 

If you are an investor in Norway, please go to

If you are an investor in Denmark, please go to

If you are an investor in Luxembourg, please go to

If you are an investor in Sweden, please go to

If you are an investor in Finland, please go to



The Lyxor ETFs on this website are undertakings for collective investment in transferable securities (UCITS) (i) domiciled in France and approved by the Autorité des Marchés Financiers (AMF) or, (ii) domiciled in Luxembourg, approved by the Commission de Surveillance du Secteur Financier (CSSF) and authorised to market their units or shares in the French Republic in accordance with the notification procedure under Article 93 of Directive 2009/65/EC. Investors should note that the prospectuses of certain Lyxor ETFs under Luxembourg law that have been notified in accordance with this procedure are only available on the website in English. A French translation of these prospectuses can be obtained upon request by sending a letter to Lyxor International Asset Management (“Lyxor”) – 17 Cours Valmy, 92987 Paris La Défense, France.


The information on this website is not intended for persons or entities that are resident, located or registered in jurisdictions that are not authorised to distribute Lyxor ETFs. As a result, the information on this website does not constitute an offer or solicitation to buy or sell units or shares in these ETFs by anyone in any jurisdiction:


(a)   in which such an offer or solicitation is unauthorised;

(b)   in which Lyxor is not qualified to make such an offer or solicitation; or 

(c)   in which it is unlawful to make such an offer or solicitation.


In particular, the Lyxor ETFs on this website are not and will not be registered under the United States Securities Act of 1933, as amended. As such, they may not be offered or sold within the United States of America, except in specific cases where transactions are exempt from registration under the Securities Act. The ETFs listed on this website may not be sold to US citizens or transferred to the United States by any other means, unless this transaction is not subject to any specific registration under US law. 


Any person from a jurisdiction to which the above-mentioned restrictions apply should inform themselves of and observe these restrictions.


This website is intended for commercial purposes and is not regulatory in nature. Although the information provided has been drawn up on the basis of sources considered to be reliable, there is no guarantee that it is accurate, complete or relevant. Some of the information on this website is provided on the basis of market data collected at a specific time and may therefore vary over time. Lyxor advises investors to read the risk factors section of the prospectus and the key investor information document carefully. These documents can be found on the website.


The net asset value (“NAV”) of Lyxor ETFs may at any time be subject to considerable price fluctuations, which in some cases may lead to the loss of all of the capital invested. Investors should note that some ETFs may be sensitive to fluctuations in the exchange rate between their reference currency and that of the underlying index, as well as of the components of the underlying index.


Before investing in a Lyxor ETF, you should carry out your own risk analysis of the product from a legal, tax and accounting perspective, rather than basing your decision solely on the information provided. If necessary, you should consult your own advisers or any other qualified professional. 


Subject to compliance with the legal obligations by which they are bound, Lyxor or any entity within the same group shall not be held liable for any financial or other consequences of an investment in the product. 



By clicking on institutional or individual above, I confirm that I have read and understood the information provided herein, and that I am resident or registered in Luxembourg.


26 Feb 2018

Capturing capex opportunities

Having covered all of our other major investment themes for this year in our recent blogs, it’s now the turn of what we believe could be widespread capex growth and its possible effects.  

Company management teams were reluctant to undertake major capital expenditure projects while the investment climate was uncertain. Despite low interest rates, higher asset prices and weak corporate confidence proved to be too much of a deterrent. However, we see this trend reversing, and expect a number of significant catalysts to prompt growth in global capex.

Chief among them is a material shift in the global economic backdrop - growth has been gaining momentum, and there is now a largely synchronised recovery across the world. Companies can now focus on replenishing their productive capacity; safe in knowledge there should be demand. 

Differing dynamics

However, the dynamics differ across the globe. The drive for higher capex looks to be strongest in the US, where tax reform should galvanise greater commitment to capital spending programmes. There are now increased tax incentives for them to do so; they can now expense all their capital expenditure for five years, with interest deductions of up to 30% of EBITDA (earnings before interest, depreciation and amortisation).

Also, the steeper-than-expected levy – 15.5% – on the trillions of dollars held overseas by US companies is likely to prompt a rapid repatriation of offshore cash. Once back in the US, it may go towards share buybacks or dividend payouts, but some, we believe, will find its way into capital expenditure programmes. Lower corporation tax rates will also give companies more money to spend.

Business confidence figures are strong, particularly among small businesses, a key ingredient for capex and employment growth. At the same time, strong profitability and cashflow generation for US companies will also remain supportive of capex trends. Companies have a lot of cash to put into motion.

There is push as well as pull. US assets are ageing. Statistics from the Bureau of Economic Analysis showed the average age of all US fixed assets to be 22.8 years in 2015. This is the oldest they have been since records began back in 1925. We believe this will prompt management teams to accelerate their investment efforts or risk losing competitiveness. 

Advances in Asia and Europe

We see capex accelerating across Asia and Europe as well, albeit for different reasons. In Japan, for example, the authorities are putting incentives in place for certain types of capital expenditure. The country needs more automation to counter the ageing of its population, which is prompting significant investment in robotics. In China, there is increasing investment in machinery, after a period of notable wage inflation. There too, companies recognise the need to automate in order to retain the global competitiveness of their products.

In Europe, companies have built up significant cash reserves after years of caution over the economic and political climate. The eurozone economy now has considerable momentum. Indeed, all member countries enjoyed accelerating growth last year. This has boosted corporate confidence and encouraged companies to put cash to work. 

Sector standouts

There are a number of sectors likely to be beneficiaries of the growth in capex. The most obvious is technology. Not only have companies held back investment, there are now new trends in which to participate. For example, software-as-a-service helps them manage technology costs more efficiently, while the move to the cloud has real advantages for security and cost. There are competitive and productivity pressures for companies. At the same time, technology stocks tend to perform well at this more mature stage of the economic cycle.

Other sectors that may benefit include the banking sector. Rising yields and greater borrowing requirements could help margins improve. We believe the oil sector may also be at the heart of additional capex spending. A more stable oil price is creating the incentive to invest in productive capacity and this is likely to come through over the next 12 months.

There are risks to this scenario. The most pressing would be a sudden resurgence in inflation and a resulting rise in interest rates. Borrowing costs are already moving higher, and the tax reform bill in the US placed some limits on the deductibility of interest rate payments. This would curtail investments funded via debt increases. However, many companies are sitting on large cash piles and as such, are relatively insensitive to interest rates.

Barring these potential detractors, we believe corporate capital expenditure may surprise to the upside over the next 12 months. This will add further support to equity markets, particularly in certain sectors, so it remains one of our key investment themes for the year ahead. 

*Source: Lyxor Cross Asset Research & Equity ETF teams. All data & opinion as at 23 February 2018 unless otherwise stated. Past performance is no guide to future returns. 

To find out more about capex, watch our latest video 

Where will Capex and tax reform take you?

Not what you were looking for?

Read more on our other key themes

Risk Warning


Fund and charge data: Lyxor ETF, correct as at 23 February 2018.

This document is for the exclusive use of investors acting on their own account and categorized either as “Eligible Counterparties” or “Professional Clients” within the meaning of Markets in Financial Instruments Directive 2004/39/EC. These products comply with the UCITS Directive (2009/65/EC). Société Générale and Lyxor International Asset Management (LIAM) recommend that investors read carefully the “investment risks” section of the product’s documentation (prospectus and KIID). The prospectus and KIID are available free of charge on, and upon request to

The products mentioned are the object of market-making contracts, the purpose of which is to ensure the liquidity of the products on the London Stock Exchange, assuming normal market conditions and normally functioning computer systems. Units of a specific UCITS ETF managed by an asset manager and purchased on the secondary market cannot usually be sold directly back to the asset manager itself. Investors must buy and sell units on a secondary market with the assistance of an intermediary (e.g. a stockbroker) and may incur fees for doing so. In addition, investors may pay more than the current net asset value when buying units and may receive less than the current net asset value when selling them. Updated composition of the product’s investment portfolio is available on In addition, the indicative net asset value is published on the Reuters and Bloomberg pages of the product, and might also be mentioned on the websites of the stock exchanges where the product is listed.

Prior to investing in the product, investors should seek independent financial, tax, accounting and legal advice. It is each investor’s responsibility to ascertain that it is authorised to subscribe, or invest into this product. This document is of a commercial nature and not of a regulatory nature. This material is of a commercial nature and not a regulatory nature. This document does not constitute an offer, or an invitation to make an offer, from Société Générale, Lyxor Asset Management (together with its affiliates, Lyxor AM) or any of their respective subsidiaries to purchase or sell the product referred to herein.

Lyxor International Asset Management (LIAM), société par actions simplifiée having its registered office at Tours Société Générale, 17 cours Valmy, 92800 Puteaux (France), 418 862 215 RCS Nanterre, is authorized and regulated by the Autorité des Marchés Financiers (AMF) under the UCITS Directive (2009/65/EU) and the AIFM Directive (2011/31/EU). LIAM is represented in the UK by Lyxor Asset Management UK LLP, which is authorized and regulated by the Financial Conduct Authority in the UK under Registration Number 435658. Société Générale is a French credit institution (bank) authorised by the Autorité de contrôle prudentiel et de résolution (the French Prudential Control Authority).

Research disclaimer

Lyxor International Asset Management (“LIAM”) or its employees may have or maintain business relationships with companies covered in its research reports. As a result, investors should be aware that LIAM and its employees may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Please see appendix at the end of this report for the analyst(s) certification(s), important disclosures and disclaimers. Alternatively, visit our global research disclosure website

Conflicts of interest 

This research contains the views, opinions and recommendations of Lyxor International Asset Management (“LIAM”) Cross Asset and ETF research analysts and/or strategists. To the extent that this research contains trade ideas based on macro views of economic market conditions or relative value, it may differ from the fundamental Cross Asset and ETF Research opinions and recommendations contained in Cross Asset and ETF Research sector or company research reports and from the views and opinions of other departments of LIAM and its affiliates. Lyxor Cross Asset and ETF research analysts and/or strategists routinely consult with LIAM sales and portfolio management personnel regarding market information including, but not limited to, pricing, spread levels and trading activity of ETFs tracking equity, fixed income and commodity indices. Trading desks may trade, or have traded, as principal on the basis of the research analyst(s) views and reports. Lyxor has mandatory research policies and procedures that are reasonably designed to (i) ensure that purported facts in research reports are based on reliable information and (ii) to prevent improper selective or tiered dissemination of research reports. In addition, research analysts receive compensation based, in part, on the quality and accuracy of their analysis, client feedback, competitive factors and LIAM’s total revenues including revenues from management fees and investment advisory fees and distribution fees.

Connect with us on linkedin